Overview


According to FutureWise analysis the market for asia pacific pharmaceutical contract manufacturing is expected to reach US$ 99.63 billion by 2031 at a CAGR of 8.92%.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Asia Pacific Pharmaceutical Contract Manufacturing Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Asia Pacific Pharmaceutical Contract Manufacturing Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.
  • Aenova Group
  • Baxter BioPharma Solutions
  • Boehringer Ingelheim
  • Catalent Inc.
  • Famar S.A.
  • Hospira, Inc.
  • Jubilant Life Sciences Ltd.
  • Lonza Group
  • Patheon Inc.
  • Pfizer CentreSource
  • Recipharm AB
  • Vetter Pharma International GmbH

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Category

  • Pharmaceutical Industry
  • Biopharmaceutical Industry

By Product

  • Active Pharmaceutical Ingredients (API)
    • Branded API Manufacturing
    • Generic API Manufacturing
  • Finished Dosage Formulations (FDF)
    • Solid Dosage
    • Oral Liquids
    • Parenteral/Injectables
    • Other FDFs

By Phase

  • Clinical Manufacturing
  • Commercial Manufacturing

By Type

  • Sterile Products
  • Non-Sterile Products

By Therapeutic Application

  • Infectious Diseases
  • Oncology
  • Metabolic Disorders
  • Cardiovascular Disorders
  • Central Nervous System
  • Pulmonary Disorders
  • Gastrointestinal Disorders
  • Other Therapeutic Applications

By Region

  • Japan
  • China
  • India
  • Australia and New Zealand
  • ASEAN
  • Rest of Asia Pacific
  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Asia Pacific Pharmaceutical Contract Manufacturing Market By Category, By Product, By Phase, By Type, By Therapeutic Application and By Region. 
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— Asia Pacific.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Asia Pacific Pharmaceutical Contract Manufacturing Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Asia Pacific Pharmaceutical Contract Manufacturing Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Asia Pacific Pharmaceutical Contract Manufacturing Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Asia Pacific Pharmaceutical Contract Manufacturing Market, By Category Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Pharmaceutical Industry
        2. Biopharmaceutical Industry

  • 8.   Global Asia Pacific Pharmaceutical Contract Manufacturing Market, By Product Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Active Pharmaceutical Ingredients (API)
         1.1. Branded API Manufacturing
         1.2. Generic API Manufacturing
        2. Finished Dosage Formulations (FDF)
         2.1. Solid Dosage
         2.2. Oral Liquids
         2.3. Parenteral/Injectables
         2.4. Other FDFs

  • 9.   Global Asia Pacific Pharmaceutical Contract Manufacturing Market, By Phase Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Clinical Manufacturing
        2. Commercial Manufacturing

  • 10.   Global Asia Pacific Pharmaceutical Contract Manufacturing Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Sterile Products
        2. Non-Sterile Products

  • 11.   Global Asia Pacific Pharmaceutical Contract Manufacturing Market, By Therapeutic Application Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Infectious Diseases
        2. Oncology
        3. Metabolic Disorders
        4. Cardiovascular Disorders
        5. Central Nervous System
        6. Pulmonary Disorders
        7. Gastrointestinal Disorders
        8. Other Therapeutic Applications

  • 12.   Asia Pacific Pharmaceutical Contract Manufacturing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Market Share Analysis and Competitive Landscape
    •   1. Asia Pacific Landscape - Key Players, Revenue and Presence
        2. Asia Pacific Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Asia Pacific Emerging Companies
        4. Asia Pacific - Market Share Analysis and Key Regional Players
        5. Asia Pacific Key Player - Growth Matrix
  • 14.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. Aenova Group
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Baxter BioPharma Solutions
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Boehringer Ingelheim
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Catalent Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Famar S.A.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Hospira, Inc.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Jubilant Life Sciences Ltd.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Lonza Group
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Patheon Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Pfizer CentreSource
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Recipharm AB
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Vetter Pharma International GmbH
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview

  • 15.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 16.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11